|Report Code: PP10137
|Report Type: Indication Pipeline Reports
Prostate cancer occurs when cells in prostate glands grow uncontrollably. Prostate is an exocrine gland that makes the fluid part of semen and lie below the bladder in front of the rectum. As per the National Institute of Health (NIH), 10.7% of all new cases of cancer in the U.S. are of prostate cancer. Moreover, according to the National Cancer Institute, prostate cancer is the second leading cause of cancer deaths in men. The symptoms of the disease include frequent urination, difficulty in holding urine, painful or burning sensation while urinating, blood in the urine, blood in semen, erectile dysfunction, and pain in the lower back or pelvis or thighs. The treatment options for prostate cancer include hormone therapy, chemotherapy and vaccine treatment.
The drug candidates of hormone refractory (castration resistant, androgen-independent) prostate cancer pipeline include, but not limited to, AT-001 and Rucaparib. Some of the companies having drugs in the hormone refractory (castration resistant, androgen-independent) prostate cancer pipeline includes GTx Inc., Immunomedics Inc., and Clovis Oncology Inc.